
Immix Biopharma, Inc.: shareholders and insiders
Price
$6.96
November 20, 2026Market cap $583M
What Ploutos Investor adds for Immix Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Nov 20, 2026, from their own Form 4 filings.
Bought on the market
$30.1K
2 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $20.0K by 2 people·no sales
- 2025: bought $10.0K by 2 people, no sales
- 2026: bought $20.0K by 2 people, no sales
- Nov 18, 2026Ilya M RachmanCEO, ChairmanKind
- Nov 18, 2026Gabriel S MorrisCFO, PresidentKind
- May 22, 2026Helen C. AdamsDirectorKind
- May 22, 2026Carey NgDirectorKind
- May 22, 2026Magda MarquetDirectorKind
- May 22, 2026Nancy T ChangDirectorKind
- May 22, 2026Yekaterina ChudnovskyDirectorKind
- May 22, 2026Jason HsuDirectorKind
- May 22, 2026Jane BuchanDirectorKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Ilya M RachmanCEO, Chairman | 1,408 | $7.10 | $10.0K | Form 4 | |
| Nov 18, 2026 | Gabriel S MorrisCFO, President | 1,418 | $7.06 | $10.0K | Form 4 | |
| May 22, 2026 | Helen C. AdamsDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Carey NgDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Magda MarquetDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Nancy T ChangDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Yekaterina ChudnovskyDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Jason HsuDirector | 6,250 | – | – | Form 4 | |
| May 22, 2026 | Jane BuchanDirector | 6,250 | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 29, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by IMMX's officers and directors from 2021 up to November 21, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- JANUS HENDERSON GROUP Ltd.Share of class14.0%
- Saturn V Capital Management LPwith 1 more personShare of class6.97%
- Eventide Asset Management, LLCwith 2 more personsShare of class5.60%
- BlackRock, Inc.Share of class5.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 14.0% | 9.78M | Aug 13, 20264 filings since Feb 17, 2026 | 13G/A | |
| Saturn V Capital Management LPwith 1 more person | 6.97% | 3.69M | Feb 17, 2026 | 13G | |
| Eventide Asset Management, LLCwith 2 more persons | 5.60% | 3.89M | Aug 14, 2026 | 13G | |
| BlackRock, Inc. | 5.50% | 4.54M | Oct 27, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+84%
- Millennium Mgmt (Englander)In the quarter-58%
- D.E. ShawIn the quarter+123%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 931.4K | +84% | $9.7M | 0.01% |
| Millennium Mgmt (Englander) | 865.9K | -58% | $9.0M | 0.01% |
| D.E. Shaw | 207.7K | +123% | $2.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.8% of its shares outstanding were held short, +3.1% since the report before.
- Shares held short
- 10.71M
- 12.8%
- Since the report before10.39M on Sep 30, 2026
- +3.1%
- 7.5
- 1.43M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 81%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 295.0K
- Nov 15, 2023: Shares held short 242.6K
- Nov 30, 2023: Shares held short 139.7K
- Dec 15, 2023: Shares held short 139.8K
- Dec 29, 2023: Shares held short 212.8K
- Jan 12, 2024: Shares held short 219.5K
- Jan 31, 2024: Shares held short 489.9K
- Feb 15, 2024: Shares held short 308.8K
- Feb 29, 2024: Shares held short 264.1K
- Mar 15, 2024: Shares held short 316.6K
- Mar 28, 2024: Shares held short 388.8K
- Apr 15, 2024: Shares held short 349.9K
- Apr 30, 2024: Shares held short 387.5K
- May 15, 2024: Shares held short 366.5K
- May 31, 2024: Shares held short 338.7K
- Jun 14, 2024: Shares held short 473.1K
- Jun 28, 2024: Shares held short 557.4K
- Jul 15, 2024: Shares held short 625.3K
- Jul 31, 2024: Shares held short 578.2K
- Aug 15, 2024: Shares held short 568.4K
- Aug 30, 2024: Shares held short 324.0K
- Sep 13, 2024: Shares held short 479.7K
- Sep 30, 2024: Shares held short 552.8K
- Oct 15, 2024: Shares held short 450.5K
- Oct 31, 2024: Shares held short 434.9K
- Nov 15, 2024: Shares held short 400.7K
- Nov 29, 2024: Shares held short 470.7K
- Dec 13, 2024: Shares held short 400.5K
- Dec 31, 2024: Shares held short 356.5K
- Jan 15, 2025: Shares held short 378.9K
- Jan 31, 2025: Shares held short 335.3K
- Feb 14, 2025: Shares held short 389.4K
- Feb 28, 2025: Shares held short 386.3K
- Mar 14, 2025: Shares held short 367.4K
- Mar 31, 2025: Shares held short 346.8K
- Apr 15, 2025: Shares held short 191.3K
- Apr 30, 2025: Shares held short 221.2K
- May 15, 2025: Shares held short 213.6K
- May 30, 2025: Shares held short 289.7K
- Jun 13, 2025: Shares held short 246.6K
- Jun 30, 2025: Shares held short 166.3K
- Jul 15, 2025: Shares held short 229.0K
- Jul 31, 2025: Shares held short 195.2K
- Aug 15, 2025: Shares held short 122.6K
- Aug 29, 2025: Shares held short 369.0K
- Sep 15, 2025: Shares held short 454.7K
- Sep 30, 2025: Shares held short 521.8K
- Oct 15, 2025: Shares held short 598.7K
- Oct 31, 2025: Shares held short 848.3K
- Nov 14, 2025: Shares held short 1.19M
- Nov 28, 2025: Shares held short 1.37M
- Dec 15, 2025: Shares held short 1.75M
- Dec 31, 2025: Shares held short 2.11M
- Jan 15, 2026: Shares held short 2.27M
- Jan 30, 2026: Shares held short 2.99M
- Feb 13, 2026: Shares held short 3.43M
- Feb 27, 2026: Shares held short 2.97M
- Mar 13, 2026: Shares held short 3.00M
- Mar 31, 2026: Shares held short 3.12M
- Apr 15, 2026: Shares held short 2.96M
- Apr 30, 2026: Shares held short 3.02M
- May 15, 2026: Shares held short 3.22M
- May 29, 2026: Shares held short 4.03M
- Jun 15, 2026: Shares held short 3.97M
- Jun 30, 2026: Shares held short 7.88M
- Jul 15, 2026: Shares held short 8.50M
- Jul 31, 2026: Shares held short 9.49M
- Aug 14, 2026: Shares held short 10.36M
- Aug 31, 2026: Shares held short 9.62M
- Sep 15, 2026: Shares held short 9.62M
- Sep 30, 2026: Shares held short 10.39M
- Oct 15, 2026: Shares held short 10.71M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading56.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 56.9% of the shares in the reported trades were short sales, against 57.1% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 56.9%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 57.1%
- Change
- -0.2 pts
- Short sales a dayon average, of 460.6K shares
- 262.1K
- More than atof 3,666 US-listed companies, same days
- 74%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 62.5%
- Oct 15, 2026: Short sales 64.8%
- Oct 16, 2026: Short sales 64%
- Oct 19, 2026: Short sales 63.2%
- Oct 20, 2026: Short sales 64.6%
- Oct 21, 2026: Short sales 77.3%
- Oct 22, 2026: Short sales 55.2%
- Oct 23, 2026: Short sales 61.9%
- Oct 26, 2026: Short sales 54.8%
- Oct 27, 2026: Short sales 44%
- Oct 28, 2026: Short sales 48.1%
- Oct 29, 2026: Short sales 40.3%
- Oct 30, 2026: Short sales 53.5%
- Nov 2, 2026: Short sales 43.9%
- Nov 3, 2026: Short sales 44.6%
- Nov 4, 2026: Short sales 45.8%
- Nov 5, 2026: Short sales 47%
- Nov 6, 2026: Short sales 64.8%
- Nov 9, 2026: Short sales 71.3%
- Nov 10, 2026: Short sales 59%
- Nov 11, 2026: Short sales 70.9%
- Nov 12, 2026: Short sales 55.1%
- Nov 13, 2026: Short sales 59.6%
- Nov 16, 2026: Short sales 55.1%
- Nov 17, 2026: Short sales 45%
- Nov 18, 2026: Short sales 46.1%
- Nov 19, 2026: Short sales 67.5%
- Nov 20, 2026: Short sales 55.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Jason HsuDirectorDirectly4.87M
- Yekaterina ChudnovskyDirectorDirectly3.25M
- Ilya M RachmanCEO and ChairmanDirectly1.14M
- Carey NgDirectorDirectly1.05M
- Nancy T ChangDirectorDirectly925.1K
- Gabriel S MorrisCFODirectly743.8K
- Helen C. AdamsDirectorDirectly181.0K
- Magda MarquetDirectorDirectly72.3K
- Jane BuchanDirectorDirectly28.7K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Jason HsuDirector | 4.87M | – | May 22, 2026 | Form 4 |
| Yekaterina ChudnovskyDirector | 3.25M | – | May 22, 2026 | Form 4 |
| Ilya M RachmanCEO and Chairman | 1.14M | – | Nov 18, 2026 | Form 4 |
| Carey NgDirector | 1.05M | – | May 22, 2026 | Form 4 |
| Nancy T ChangDirector | 925.1K | – | May 22, 2026 | Form 4 |
| Gabriel S MorrisCFO | 743.8K | – | Nov 18, 2026 | Form 4 |
| Helen C. AdamsDirector | 181.0K | – | May 22, 2026 | Form 4 |
| Magda MarquetDirector | 72.3K | – | May 22, 2026 | Form 4 |
| Jane BuchanDirector | 28.7K | – | May 22, 2026 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.20%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.12%
- IWCiShares Micro-Cap ETFWeight in the fund0.09%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
8 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 31
- Q4 2025: Managers 67
- Q1 2026: Managers 77
- Q2 2026: Managers 109
Institutional investors by quarter
The fund managers holding IMMX, quarter by quarter, from Q4 2021 to Q2 2025, 15 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 109 managers held 56.22M shares, worth $580M. During the quarter 44 opened a position, 13 closed one, 32 added and 13 trimmed.
The largest holders, Q2 2026
- Jupiter TopcoIn the quarter
- Saturn V Capital ManagementIn the quarter+26%
- Eventide Asset ManagementIn the quarter+53%
- State StreetIn the quarter×15.6
- BlackRockIn the quarter+538%
- Deep Track CapitalIn the quarter
- Vanguard Capital ManagementIn the quarter+40%
- Opaleye ManagementIn the quarter
- Millennium Mgmt (Englander)In the quarter+18%
- UBS GroupIn the quarter×25.3
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Jupiter Topco | 9.78M | $101M | |
| Saturn V Capital Management | 4.66M | +26% | $48M |
| Eventide Asset Management | 3.89M | +53% | $40M |
| State Street | 3.00M | ×15.6 | $31M |
| BlackRock | 2.99M | +538% | $31M |
| Deep Track Capital | 2.78M | $29M | |
| Vanguard Capital Management | 2.51M | +40% | $26M |
| Opaleye Management | 2.35M | $24M | |
| Millennium Mgmt (Englander) | 2.07M | +18% | $21M |
| UBS Group | 1.94M | ×25.3 | $20M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Immix Biopharma's filings show?
Who buys and sells is one part of Immix Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IMMX's insiders bought or sold?
From May 29, 2026 to Nov 20, 2026 Immix Biopharma's insiders bought $20.0K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold IMMX?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $9.7M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.